Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Rev Esp Quimioter ; 36(4): 380-391, 2023 Aug.
Article in English | MEDLINE | ID: covidwho-2292875

ABSTRACT

Recipients of solid organ transplants (SOT) are at higher risk of infection by SARS-CoV-2 virus especially due to chronic immunosuppression therapy and frequent multiple comorbid conditions. COVID-19 is a potentially life-threatening disease in SOT recipients, with an increased likelihood of progressing to severe disease, with the need of hospitalization, admission to the intensive care unit (ICU) and mechanical ventilatory support. This article presents an updated review of different aspects related to the outcome of COVID-19 in SOT recipients. In nvaccinated SOT recipients, COVID-19 is associated with a high mortality rate, in-patient care and ICU admission, and impaired graft function or rejection in severe disease. In vaccinated SOT recipients even after full vaccination, there is a reduction of the risk of mortality, but the course of COVID-19 may continue to be severe, influenced by the time from transplant, the net state of immunosuppression and having suffered graft rejection or dysfunction. SOT recipients develop lower immunity from mRNA vaccines with suboptimal response. Treatment with mAbs provides favorable outcomes in non-hospitalized SOT recipients at high risk for severe disease, with lower rates of hospitalization, emergency department visits, ICU care, progression to severe disease, and death. However, broad vaccination and therapeutic options are required, particularly in light of the tendency of the SARS-CoV-2 virus to adapt and evade both natural and vaccine-induced immunity.


Subject(s)
COVID-19 , Organ Transplantation , Humans , SARS-CoV-2 , Transplant Recipients , Antibodies, Monoclonal/therapeutic use , Organ Transplantation/adverse effects
2.
Rev Esp Quimioter ; 35 Suppl 3: 54-62, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2253655

ABSTRACT

SARS-CoV-2 infection has had a major impact on donation and transplantation. Since the cessation of activity two years ago, the international medical community has rapidly generated evidence capable of sustaining and increasing this neccesary activity. This paper analyses the epidemiology and burden of COVID-19 in donation and transplantation, the pathogenesis of the infection and its relationship with graft-mediated transmission, the impact of vaccination on donation and transplantation, the evolution of donation in Spain throughout the pandemic, some lessons learned in SARS-CoV-2 infected donor recipients with positive PCR and the applicability of the main therapeutic tools recently approved for treatment among transplant recipients.


Subject(s)
COVID-19 , Organ Transplantation , Humans , SARS-CoV-2 , Pandemics , Tissue Donors
4.
Value in Health ; 25(1):S128, 2022.
Article in English | EMBASE | ID: covidwho-1650264

ABSTRACT

Objectives: With over 172 million cases and 3.7 million deaths worldwide, the COVID-19 pandemic has overwhelmed health systems forcing governments to implement non-pharmacological interventions (NPI) to control the spread of the disease. Spain was one of the first and most severely impacted countries by the COVID-19 pandemic. The models developed herein aim to assess the clinical and economic consequences of such NPI, based on the Spanish case. Methods: Two separate models were developed to assess the epidemiological and economic impacts of different NPI (i.e. social restrictions and testing) on the COVID-19 pandemic. First, a dynamic, modified, Susceptible-Exposed-Infectious-Removed (SEIR) model was developed. Then, the output from the SEIR model was used in the second model to estimate direct healthcare costs and Gross Domestic Product (GDP) changes using a regression model which correlated different NPI and GDP changes observed across 42 countries. Overall, 13 scenarios combining different NPIs based on social restrictions and testing rates were simulated through both models. Results: Based on the results from the SEIR simulation both increased social restrictions (Composite COVID-19 Stringency Index≥73) and increased testing rates (positivity≤1%) would manage to control the COVID-19 spread. However, notable differences are observed in terms of direct healthcare costs and GDP impact. Policies entailing increased testing rates translated into higher healthcare costs and lower GDP decline (vs. same quarter from previous year), whereas increased social restrictions are correlated with greater GDP declines, with differences of up to 4.4% points among scenarios. Increased test sensitivity also leads to higher reductions on cases, hospitalizations and deaths. Conclusions: Increased testing appears to be able to control the COVID-19 pandemic while minimizing the GDP impact. These models may provide evidence for decision makers during future pandemics and in countries where vaccination rates are still low helping to better balance health and socioeconomic concerns.

6.
Rev Esp Quimioter ; 34(6): 599-609, 2021 Dec.
Article in Spanish | MEDLINE | ID: covidwho-1498473

ABSTRACT

Pneumonia is a major cause of global mortality in developed countries. The adequacy of the antibiotic treatment is essential for the good evolution of the patients. When selecting the antimicrobial, the severity of the patient, the characteristics of the antibiotics, and the profile of the patient to be treated should be considered. Recommendations for the selection of antibiotic treatment may differ between the patient who requires admission and the one who can be treated as outpatient. Beta-lactams, fluoroquinolones, and macrolides are the most widely used antimicrobials in this last circumstance. However, not all are the same in terms of efficacy, safety and ecological impact. This review delves into the aforementioned aspects to improve decision-making and offers concrete recommendations for the selection of antibiotic treatment. Likewise, it includes recommendations for performing sequential therapy. Finally, a brief review is made about the impact of SARS-CoV-2 infection on this pathology.


Subject(s)
COVID-19 , Community-Acquired Infections , Pneumonia , Community-Acquired Infections/drug therapy , Humans , Pneumonia/drug therapy , SARS-CoV-2 , beta-Lactams/therapeutic use
7.
Revista Espanola de Quimioterapia ; 34:1, 2021.
Article in English | EMBASE | ID: covidwho-1486885
8.
Rev Esp Quimioter ; 34 Suppl 1: 76-80, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1449591

ABSTRACT

After more than a year of pandemic, the international medical community has changed the perception of fear to one of respect for SARS-COV-2. This has been the consequence of the integral study of all the dimensions of the disease, from viral recombinant capacity to transmissibility, diagnosis, care and prevention. This document summarizes the main strategic lines of study and approach to the pandemic in Madrid.


Subject(s)
COVID-19 , Pandemics , Humans , Pandemics/prevention & control , SARS-CoV-2
9.
Rev Esp Quimioter ; 34 Suppl 1: 46-48, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1449583

ABSTRACT

Detection of SARS-CoV-2 proteins is commercially available in the form of lateral-flow rapid antigen test for the point-of-care diagnosis of COVID-19. This platform has been validated for symptomatic and asymptomatic individuals, for diagnosis or screening, and as part of single or sequential diagnostic strategies. Although in general less sensitive than amplification techniques, antigen tests may be particularly valid during the first days of symptoms and to detect individuals with greater viral load, thereby with enhanced chances of viral transmission. The simplicity of antigen tests make them very suitable to discard infection in settings with low pretest probability, and to detect infection in case of higher chances of having COVID-19.


Subject(s)
COVID-19 , COVID-19 Nucleic Acid Testing , Humans , Mass Screening , SARS-CoV-2 , Sensitivity and Specificity
11.
Rev Esp Quimioter ; 34(4): 280-288, 2021 08.
Article in English | MEDLINE | ID: covidwho-1147348

ABSTRACT

We describe the most widely used temporary hospital in Europe during the first pandemic wave, its structure, function, and achievements. Other models of care developed during the pandemic around the world were reviewed including their capacity, total bed/ICU bed ratio and time of use. We particularly analyzed the common and differential characteristics of this type of facilities. IFEMA Exhibition Center was transformed into a temporary 1,300-bed hospital, which was in continuous operation for 42 days. A total of 3,817 people were treated, generally patients with mild to moderate COVID-19, 91% of whom had pneumonia. The average length of stay was 5 to 36 days. The most frequent comorbidities were hypertension (16.5%), diabetes mellitus (9.1%), COPD (6%), asthma (4.6%), obesity (2.9%) and dementia (1.6%). A total of 113 patients (3%) were transferred to another centers for aggravation, 19 (0.5%) were admitted to ICU and 16 patients (0.4%) died. An element of great help to reducing the overload of care in large hospitals during peaks of health emergencies could be these flexible structures capable of absorbing the excess of patients. These must be safe, breaking domestic transmission and guarantee social and emotional needs of patients. The success of these structures depends on delimitation in admission criteria taking into account the proportion of patients who may require, during admission, assistance in the critical care area.


Subject(s)
COVID-19 , Hospital Administration , Hospitals/statistics & numerical data , Pandemics , Critical Care , Europe , Humans , Intensive Care Units
12.
Rev Esp Quimioter ; 33(6): 466-484, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-875201

ABSTRACT

The high transmissibility of SARS-CoV-2 before and shortly after the onset of symptoms suggests that only diagnosing and isolating symptomatic patients may not be sufficient to interrupt the spread of infection; therefore, public health measures such as personal distancing are also necessary. Additionally, it will be important to detect the newly infected individuals who remain asymptomatic, which may account for 50% or more of the cases. Molecular techniques are the "gold standard" for the diagnosis of SARS-CoV-2 infection. However, the massive use of these techniques has generated some problems. On the one hand, the scarcity of resources (analyzers, fungibles and reagents), and on the other the delay in the notification of results. These two facts translate into a lag in the application of isolation measures among cases and contacts, which favors the spread of the infection. Antigen detection tests are also direct diagnostic methods, with the advantage of obtaining the result in a few minutes and at the very "pointof-care". Furthermore, the simplicity and low cost of these tests allow them to be repeated on successive days in certain clinical settings. The sensitivity of antigen tests is generally lower than that of nucleic acid tests, although their specificity is comparable. Antigenic tests have been shown to be more valid in the days around the onset of symptoms, when the viral load in the nasopharynx is higher. Having a rapid and real-time viral detection assay such as the antigen test has been shown to be more useful to control the spread of the infection than more sensitive tests, but with greater cost and response time, such as in case of molecular tests. The main health institutions such as the WHO, the CDC and the Ministry of Health of the Government of Spain propose the use of antigenic tests in a wide variety of strategies to respond to the pandemic. This document aims to support physicians involved in the care of patients with suspected SC2 infection, in the context of a growing incidence in Spain since September 2020, which already represents the second pandemic wave of COVID-19.


Subject(s)
Antigens, Viral/blood , COVID-19 Serological Testing/methods , COVID-19/diagnosis , Consensus , Pandemics , SARS-CoV-2/immunology , Acute Disease , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Algorithms , COVID-19/epidemiology , COVID-19/mortality , COVID-19/transmission , COVID-19 Nucleic Acid Testing/standards , COVID-19 Serological Testing/standards , Child , Child, Preschool , Contact Tracing , Emergencies , Female , Humans , Incidence , Infant , Male , Middle Aged , Nasopharynx/virology , Sensitivity and Specificity , Spain/epidemiology , Specimen Handling/methods , Specimen Handling/standards , Young Adult
14.
Rev Esp Quimioter ; 33(4): 258-266, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-530953

ABSTRACT

OBJECTIVE: The diagnosis of SARS-CoV-2 infection is crucial for medical and public health reasons, to allow the best treatment of cases and the best control of the pandemic. Serology testing allows for the detection of asymptomatic infections and 19-COVID cases once the virus has been cleared. We analyzed the usefulness of the SARS-CoV-2 rapid test of Autobio and tried to correlate its pattern with the severity of COVID19 infection. METHODS: We analyzed the accuracy and clinical usefulness of a point-of-care IgM and/or IgG test for SARS-CoV-2 in 35 COVID-19 patients [12 (34.3%) mild-moderate and 23 (65.7%) severe-critical] admitted to a field hospital in Madrid, as well as in 5 controls. RESULTS: The mean time from the first day of symptoms to the antibody test was 28 days (SD: 8.7), similar according to the severity of the disease. All patients with SARS-CoV-2 PCR+ showed the corresponding IgG positivity, while these results were negative in all control individuals. A total of 26 (74%) cases also presented with positive IgM, 19 (83%) were severe-critical cases and 7 (58%) were mild-moderate cases. The IgM response lasted longer in the severe critical cases (mean: 29.7 days; SD: 8.4) compared to the moderate cases (mean: 21.2 days; SD: 2.0).. CONCLUSIONS: Rapid serology tests are useful for the diagnosis of patients with COVID-19 (mainly IgG detection) and may also be correlated with the severity of the infection (based on IgM detection).


Subject(s)
Antibodies, Viral/blood , Betacoronavirus/immunology , Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , Point-of-Care Testing , Adult , Aged , Asymptomatic Infections , COVID-19 , COVID-19 Testing , Coronavirus Infections/virology , Cross-Sectional Studies , Female , Humans , Immunoassay/methods , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Pandemics , Pneumonia, Viral/virology , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Sensitivity and Specificity , Severity of Illness Index , Symptom Assessment/statistics & numerical data , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL